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Background: We evaluated the relationship of the apoptotic activity index (AI) and the standardized
mitotic-apoptotic ratio (SMI/AI) with clinicopathological features and prognosis in Libyan female breast cancer (BC)
patients. We then compared our results with corresponding results in Finnish and Nigerian female BC patients.
Methods: Histological samples of breast carcinoma from 130 patients were retrospectively studied: an estimation of the
apoptotic activity per square millimeter (expressed as apoptotic activity index (AI)), and standardized mitotic-apoptotic
ratio (SMI/AI) was made, and the results compared with the clinicopathological features and the patient’s survival.
Results: There was a statistically significant correlation between the AI and most of the clinicopathological features;
the strongest association was observed for clinical stage lymph node (LN) status (P= 0.005). There were also
correlations between AI and histological grade (P= 0.035), large tumor size (P= 0.011) and the clinical stage (P= 0.009).
There were, however, prominent AI differences between Libyan, Nigerian and Finnish populations. The mean values of
AI and SMI/AI in Libyan BC patients were 12.8 apoptotic figures per square millimeter and 2.8, respectively. The Libyan
AI is slightly higher than in Nigeria, but much higher than in Finland. The differences between countries are seen
throughout the samples as well as being present in certain subgroups. The survival analysis indicated that short
survival time was associated with high apoptotic indices values and so can identify aggressive tumors and provide
significant prognostic support. The cutoff (4 and 18 apoptosis/mm2) of AI might be applied as a quantitative criterion
for Libyan BC to separate the patients into good, moderate and bad prognosis groups.
Conclusions: The results indicated that the differences in AI among the three countries may be due to the known
variation in the distribution of genetic markers in these populations. Improvement in health care and introduction of
screening programs, however, could be very helpful in the Libyan population.
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Apoptosis or programmed cell death is the carefully
coordinated collapse and death of the cell, associated
with nuclear DNA fragmentation and protein degrad-
ation, usually followed by rapid engulfment of the
remaining nuclear material by neighboring cells. It is an
essential part of life for every multicellular organism.
Apoptosis plays a major role throughout life, from em-
bryonic development to senescence. Apoptosis is needed
to destroy cells infected with viruses, cells with DNA
damage, and cancer cells. Several oncogenes, such as
Bcl-2 [1], c-myc [2] and p53 [3] are involved in the* Correspondence: fabdalla@utu.fi
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reproduction in any medium, provided the orregulation of apoptosis. The role of apoptosis in onco-
genesis is currently being studied intensively in breast
cancer (BC). There are several methods to detect
apoptosis.
Immunohistochemistry can detect death receptors and
ligands, but also morphologic identification through mi-
croscopy is possible. Apoptotic count has predictive and
prognostic roles in survival in BC in Caucasian women
[4]. Apoptosis count has been shown to be a prognostica-
tor in African BC [5]. Earlier studies have shown signifi-
cant differences, at a population level, of proliferative
activity and nuclear morphometric features among Libyan,
Finnish and Nigerian BC [6,7].
This study is designed to evaluate how these observa-
tions are reflected in the pattern of the apoptotic activity
in Libyan BC. In addition, an attempt will be made to es-
timate the prognostic role of apoptotic activity in help-
ing to identify the high-risk group of BC patients.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Average estimates of apoptotic activity, and
balance between proliferative and apoptotic activity in




AI (SD) P value SMI/AI
(SD)
P value
Whole material 130 12.8 (9.6) 2.8 (2.0)
Age groups
<40 49 13.3 (9.5) 2.9 (2.2)
40-49 32 9.9 (9.9) 0.12 2.4 (1.5) 0.38
≥50 49 14.3 (9.4) 3.0 (2.0)
Menopausal status
Premenopausal 80 12.07 (9.7) 2.76 (2.0) 0.54
(age <50 yrs) 0.26
Postmenopausal 50 14.05 (9.5) 2.98 (2.0)
(age≥ 50 yrs)
Tumor size
<3 8 4.5 (5.7) 0.011 2.8 (1.9) 0.75
≥3 122 13.4 ( 9.6) 3.2 (2.2)
Lymph node (LN) status
LN- 27 8.3 (7.0) 0.005 2.5 (1.3) 0.73
LN+ 103 14.0 (9.9) 2.9 (2.1)
Clinical stage
Stage1 6 5.0 (5.1) 3.0 (2.3)
Stage 2 44 10.2 (6.7) 0.009 2.4 (1.0) 0.30
Stage 3 64 14.5 (10.5) 2.9 (1.9)
Stage 4 16 16.4 (11.4) 3.4 (0.8)
Histological grade
1 10 5.9 (5.7) 0.035 2.0 (1.1) 0.43
2 70 12.7 (7.4) 3.0 (2.1)
3 50 14.5 (9.0) 2.8 (1.8)
Histological type
Invasive ductal 95 13.3 (10.6) 0.61 2.9 (2.0) 0.61
Invasive lobular 13 10.8 (5.8) 3.2 (2.5)
Other carcinomas 22 12.0 (6.7) 2.8 (2.0)
AI apoptotic activity index, BC breast cancer, SMI/AI standardized mitotic-
apoptotic ratio, SD standard deviation.
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Clinicopathological features
The study was performed on paraffin-embedded samples
from Libyan female BC patients. All cases were diag-
nosed at the Department of Pathology, African Oncology
Institute, Sabratha, Libya, and Tripoli Medical Center,
Tripoli, Libya during the years 2000 to 2006. Patients
were excluded from this study on the basis of the follow-
ing exclusion criteria: histopathology was done else-
where than in the mentioned study centers, patient
history, medical files or specimens were not found, the
follow-up was less than three months, and paraffin
blocks were not available for recutting. After exclusion
of patients’ samples, 130 patients remained in the study.
A total of 115 patients were treated with modified radical
mastectomy with axillary clearance. Fifteen patients were
unfit for surgery due to distant metastases. Diagnostic
biopsies were used for this study, a detailed history and
clinicopathological features (age, menopausal status, tumor
size, stage and grade, and lymph node status) were col-
lected from patient files (Tables 1 and 2). The mean age at
the time of diagnosis was 46.5 (SD±13.4) years; 4.6%,
33.8%, 49.2% and 12.3% of patients were at stages 1, 2, 3,
and 4, respectively.
The significance of the correlation of stage features
and proliferative features are shown as P values evalu-
ated with ANOVA and t test. *T stage, diameter of the
primary neoplasm; **N stage, lymph node status: extent
of lymph node involvement; ***M stage, distant metasta-
sis: present/absent. AI, apoptotic activity index; BC,
breast cancer; SMI/AI, standardized mitotic-apoptotic
ratio; SD, standard deviation.
The permission for tumor sample collection has been
obtained from the Libyan National Authority for Medical
Affairs. This study is a part of BC studies, permission for
which has been obtained from the local ethics committee
of National Cancer Institute in Misurata, Libya.
Follow-up and treatment
The follow-up data were collected from patient files.
Follow-up time ranged from four to seventy-eight
months, Average follow-up was 32.9 months. Some
patients were lost from follow-up. BC was recorded as
the underlying cause of death for 34 patients. Three
cases died of causes unrelated to BC and were not
included in the survival analysis. No autopsies were per-
formed. The survival period was defined as the time
from diagnosis either to the time of death or to the date
on which the patient was known to be alive.
Histological methods
The tumor diameter was measured after surgical re-
moval in three dimensions, then biopsy specimens were
fixed in buffered formalin (pH 7.3), and embedded inparaffin. Sections of 5 μm thickness were stained with
hematoxylin and eosin stain. The histological typing in
our study was based on the International Histological
Classification of Tumours 1981, and grading of tumors
was done according the modified Bloom Richardson
histopathological grading system. There were ninety-five
invasive ductal carcinomas (73.1%), thirteen invasive
lobular carcinomas (10%), seven mixed ductal and lobu-
lar carcinomas (5.4%), six medullary carcinomas (4.6%),
three papillary carcinomas (2.3%), five mucinous carcin-
omas (3.8%), and one metaplastic carcinoma (0.8%).
In identifying the apoptotic bodies, we applied criteria
described by van de Schepop et al. [8]. Apoptotic cells
were characterized by shrunken acidophilic bodies with
Table 2 Mean estimates of apoptotic activity in different
TNM and clinical stages of 130 Libyan female BC
patients, (*T= diameter of tumor, **N = lymph node
status, ***M= distant metastasis; present or absent)
Group Number
of patients
AI (SD) P value SMI/AI
(SD)
P value
*T Stage 0.007 0.06
T1 6 4.0 (5.5) 3.4 (2.6)
T2 45 10.4 (6.8) 2.5 (1.2)
T3 44 15.5 (10.7) 2.8 (2.0)
T4 35 14.1 (10.6) 3.3 (2.6)
**N Stage 0.007 0.02
N0 27 8.3 (7.0) 2.5 (1.3)
N1 69 12.3 (8.2) 3.0 (2.0)
N2 32 17.0 (12.2) 2.7 (2.2)
N3 2 26.0 (4.6) 2.4 (1.4)
***M Stage 0.02 0.013
M0 114 12.3 (9.3) 2.7 (1.6)
M1 16 16.4 (11.4) 4.0 (3.4)
Clinical stage
Stage 1 6 5.0 (5.1) 3.0 (2.3)
Stage 2 44 10.2 (6.7) 0.009 2.4 (1.0) 0.30
Stage 3 64 14.5 (10.5) 2.9 (1.9)
Stage 4 16 16.4 (11.4) 3.4 (0.8)
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The apoptotic cells were separated from their neighbors
and lacked associated inflammatory reaction. Counting
was carried out in the most cellular region at tumor per-
iphery, avoiding areas of necrosis, inflammation, in situ
carcinoma, and calcification. A five-week training pro-
gram on apoptotic counting was based on a set of ten
Libyan female BC samples. During that period, counts
were repeated on ten separate occasions, two to four
days apart. We used an Olympus laboratory microscope
(x40, objective lens magnification, numerical aperture
0.75, field diameter, 490 μm; Olympus Corp, Tokyo,
Japan). The number of apoptotic bodies in 10 con-
secutive fields from the most cellular area of the sam-
ple was the apoptotic activity (AA). The volume
fraction-corrected AI or AI gives the apoptotic count
as the number of apoptotic bodies by the area of the
neoplastic tissue in the microscopic fields. This is the
number of apoptosis in 10 consecutive fields cor-
rected for the volume fraction and field size. In this
method, the area fraction (as an estimate of volume
fraction) of neoplastic tissue in the microscopic field
is evaluated simultaneously with the apoptotic count





, where k = 100\πr², r is the radius
of the microscopic field, AA is the number of apoptotic
bodies in the studied field and Vv is the volume fraction
(estimated by the area fraction, as a percentage) of malig-
nant epithelium in the studied field. The ratio of SMI
and AI (SMI/AI) was also calculated to evaluate the bal-
ance between cell proliferation and cell death.Statistical analysis
The variables of the material were grouped into logical
classes and descriptive statistics calculated for the continu-
ous variables using SPSS 15.0 for Windows. For survival
analysis, Kaplan-Meier curves were plotted, and differences
between the curves analyzed using the logrank test. The AI
thresholds were the cutoff points showing curve separation
with the highest statistical significance. Univariate analysis
was performed to evaluate the distribution of AI, and stan-
dardized mitotic-apoptotic ratio (SMI/AI) within clinico-
pathological factors. P values below 0.05 were regarded as
significant. Student t tests and ANOVA were also used to
test differences between the groups.Results
Correlation of AI and SMI/AI with the clinicopathological
features
The clinical characteristics of the Libyan female BC
patients (n= 130) and average estimate of AI and SMI/AI
ratio are described in Tables 1 and 2. The distributions of
the values are shown in Figures 1 and 2. The relationshipof SMI and AI is shown in Figure 3. Clearly, AI is much
smaller than SMI. The regression line shows there is a
positive relationship between SMI and AI with r = 0.446,
P< 0.001 The AI in the whole material, and in different
subgroups defined by the menopausal status, lymph node
status, tumor size, histological grade, histological type,
clinical stage, are shown in Table 2, and TNM stage in
Table 3. The highest significance of correlation is shown
between clinical lymph node status and the AI (P=0.005).
Higher values also seen in large tumors, and those of
higher histological grade and advanced clinical stage with
P values 0.011, 0.035 and 0.009, respectively. The differ-
ence in the AI between invasive ductal carcinoma and
lobular carcinoma was statistically insignificant (P=0.35)
(Table 3). However, SMI/AI does not show a significant
relationship with histopathological features.
Quantitative relationship between SMI and AI
Surprisingly, the ratio of SMI/AI in Libyan material is
less than previous work on Nigerian material and close
to the results on Finnish material.
Correlation of AI with the survival outcome
AI was a significant predictor of disease-specific survival
(DSS) in the overall material and was negatively corre-
lated with survival time. The analysis for determination













Figure 1 Distribution of SMI/AI values in 130 Libyan female BCs.
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rounded by less significant cut points. The analysis using
Kaplan-Meier curves of AI indicated that short survival
time was correlated with high apoptotic activity tumors
(Figures 4 and 5).
Discussion
This study is a continuation of our efforts to further eluci-
date the biology of Libyan BC and to compare our results
with the corresponding results of Finnish, and Nigerian
female BC patients and also to identify more effective











Figure 2 Distributions of AI in 130 cases of Libyan BC.aid therapeutic decision making. The aim of the present
study was to cast further light on the issues related to
prognostication of BC, while assessing the value of apop-
totic activity as an independent prognostic factor. In this
study, we focused on stage I to IV disease, where molecu-
lar and other markers may help pinpointing a subgroup
of patients who would eventually benefit from the use of
adjuvant therapy for their disease. This important deci-
sion involves a careful weighing of the risks of toxicity
and complications against the potential curability of the
disease [11]. It is well established that early BC can be
cured with radical surgical resection [12].AI
50.0040.0030.00
Figure 3 Correlation between SMI and AI in 130 Libyan female BCs. Clearly, there is a correlation (P <0.001), but the correlation coefficient is
low (r = 0.193).
Table 3 Average estimates of apoptotic activity among 130 Libyan female breast cancer patients
Group Number AI (SD) Nigeria P value Number AI (SD) Finland P value Number AI (SD) Libya P value
Whole material 300 9.6 (14.8) 285 5.2 (6.1) 130 12.8 (9.6)
Menopausal status
Premenopausal 223 10.1 (16.3) 0.333 93 5.6 (6.4) 0.44 80 12.07 (9.7) 0.26
Postmenopausal 77 8.2 (9.3) 192 5.0 (6.0) 50 14.05 (9.5)
Lymph node status
LN- 65 7.6 (10.6) 0.185 188 5.3 (6.8) 0.514 27 8.3(7.0) 0.005
LN+ 235 10.2 (15.7) 97 4.8 (4.8) 103 14.0 (9.9)
Histological grade
1 44 4.0 (7.1) 67 2.9 (4.8) 10 5.9 (5.7)
2 119 8.6 (11.5) 0.012 173 4.5 (4.9) <0.001 70 12.7 (7.4) 0.035
3 137 12.4 (19.8) 45 11.1 (8.4) 50 14.5 (9.0)
Histological type
Invasive ductal 242 10.3 (16.7) 0.070 231 5.9 (6.5) 0.017 95 13.3 (10.6) 0.35
Other carcinoma 58 5.3 (8.4) 54 2.1 (2.3) 35 11.5 (6.3)
Stage
1 65 7.6 (10.6) 95 4.5 (5.1) 6 5.0 (5.1)
2 75 10.1 (11.7) 0.185 171 5.7 (6.9) 0.139 44 10.2 (6.7) 0.009
3 98 10.2 (20.3) 19 4.1 (2.7) 64 14.5 (10.5)
4 62 10.2 (11.4) *NA NA 16 16.4 (11.4)
Results are compared with Finnish and Nigerian patients in different subgroups.
P value gives the statistical significance of the relationship between apoptotic counts (AI) and characteristics of the patient groups (t test, X² test, ANOVA). *NA not
available. AI apoptotic activity index: SD standard deviation.















p = 0.013 
AI <  4 
AI ≥  4 
Figure 4 Disease-specific survival (DSS) for 130 Libyan patients with BC divided according to AI cut point of four. The difference
between the curves is highly significant (logrank P= 0.013).
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with lymph node-negative (LN-) BC die of recurrent dis-
ease. Prediction of disease outcome in individual patients
after curative resection is still far from reliable [13]. How-
ever, there is some hope and our results already suggest
that counting of apoptotic body could be used to help in
this decision. Apoptosis has been recognized as one of the
features of BC cells that distinguish them from normal













p =  0.001 
Figure 5 Disease-specific survival (DSS) for 130 Libyan patients with B
the curves is highly significant (logrank P= 0.001).and today many researches consider that induction of
apoptosis can be useful as a potential therapeutic target
[14,15]. In addition, more rational decisions can be made
as soon as we learn more of markers and diagnostic tools
in accurate prediction of the disease outcome in individual
patients [16,17].
On the basis of the present results, we believe that this
detection can be improved using the assessment of
apoptotic count in the primary tumors, and in thisnths
806040
AI <18 
AI ≥ 18 
C divided according to AI cut point of 18. The difference between
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very important. In this study, we compared the two
methods for counting apoptosis, and found both of them
significantly provide the most consistent and meaningful
correlations to the clinicopathological variables. In the
present cohort, several interesting and important obser-
vations were made, all implicating that the quantitatively
measurable apoptotic bodies of tumor cells could pro-
vide significant prognostic information in BC.
First, a significant correlation was shown between apop-
totic count and tumor grade. Several studies concluded
that apoptosis is strongly correlated to the histological
grade of ductal carcinoma, in that poorly differentiated
tumors show higher AI than well differentiated tumors
[1,18,19]. Our results were consistent with these findings.
With regard to LN involvement, a trend with high sig-
nificance was observed between AI and LN involvement;
79% of the tumors with LN involvement showed high
AI. The preferential high AI in LN metastases is consist-
ent with the view of clonal selection of tumor cells with
apoptotic activity, conferring them a growth advantage
with a higher potential of metastasis. This suggests that
tumors with higher AI might be more aggressive and
more likely to be associated with LN involvement at
diagnosis, and was associated with shorter disease-
specific survival. Many studies [19,20] also reported a
similar significant correlation between high AI and axil-
lary lymph node involvement and correlated them with
the number of involved nodes.
Therefore, AI seems to be an indicator of poor prog-
nosis in BC as well and was shown to be correlated with
tumor stage. Our present observations are fully consist-
ent with a previous report by Zhang et al. [19], confirm-
ing that 62% of the patients with advanced disease
(stages III and IV) have higher AI tumors. Furthermore,
AI in stages III and IV tumors was significantly higher
than in stages I and II disease (P= 0.009), implicating a
direct relationship between AI and the stage of the dis-
ease; higher AI is associated with more advanced stage
and propensity to develop metastatic disease.
However, Lipponen et al. [9] did not show same trend.
Part of these variations and discrepant observations might
be explained by the inconsistencies in the methodological
technical aspects of the measurement of the AI, which
may refer to the number of apoptotic cells per square
millimeter of neoplastic tissue in the section [5,10] or the
percentage of cells in the section that are apoptotic [1,21].
In addition, it is well known that aggressive tumors consist
of large areas of necrosis that may affect the identification
of apoptotic cells in conventional sections, especially when
the tumor is also heavily infiltrated by inflammatory cells.
Special staining techniques may identify cells that contain
fragmented DNA as a result of causes not related to apop-
totic cell death. Moreover, introducing of some otherquantitative tools, such as immunohistochemical staining
and RT-PCR, could help in overcoming this problem, by
finding biological markers that are more reliable to detect
the apoptosis on a molecular basis.
Interestingly, 16% of our patients had metastasis at diag-
nosis, strengthening the hypothesis that BC is a systemic
disease from presentation [22]. Most of these patients
showed higher AI than others with local disease. This is in
support of the hypothesis of Mommers et al. [23] who
suggested that proliferation is more important than apop-
tosis in the transformation from preinvasive carcinoma to
invasive type. On the other hand, apoptosis may play a
major role in the advanced stages of BC progression.
Obviously, one of the most important observations of
the present study is the one linking AI with the disease
outcome, that is, the appearance of recurrence and long-
term disease-specific survival (DSS). This is clinically rele-
vant because a number of BC patients of different stages
are at high risk of recurrence, it would be of paramount
importance to develop reliable markers that would accur-
ately predict those patients to be considered for adjuvant
therapy. In univariate (Kaplan-Meier) survival analysis, AI
was also a significant predictor of DSS, and not unexpect-
edly, AI was more often higher in patients who eventually
died of their disease as compared with those who were
alive at the completion of the follow-up, and this differ-
ence was significant (P=0.001, Figure 5). These data
clearly implicate that BC with high AI is at high risk for
local or distant recurrence and, because of the high ad-
verse prognostic impact of disease recurrence; these
patients are also more likely to die of their disease [20]. To
avoid this, these patients should be appropriate candidates
for intensive follow-up and targeted therapeutic strategy.
Interestingly, although our study used similar method-
ology of the earlier study of Ikpatt et al. [24], it showed sig-
nificance differences between BC in Libya compared with
the Nigeria and Finland population. There was a significant
difference in the whole material. The apoptotic and prolif-
erative differences between Central African, North African
and European patients may partly be related to biological
differences and variation in genetic marker distribution
between Central and North African, and European popula-
tions [25]. Our study has also shown difference between
Libyan and Nigerian subgroups, further strengthening our
suggestion of biological differences between North and
sub-Saharan African populations. Studies of ethnic differ-
ences in BC pathological features are limited, except for
those between African American women, and Caucasian
American women. African American women are known to
have aggressive BC compared with Caucasian American
women [26,27].
Interestingly, our quantitative analysis of both SMI and
AI values demonstrates strong correlation (Figure 3).
This quantitative relationship between SMI and AI has
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regression analysis has been suggested that SMI is the
most important determinant of AI [9]. Other markers for
proliferation such as Ki-67 [1,21], also have been found
to be highly significantly related to AI. Our finding shows
that standard mitotic-apoptotic ratio is low, which is near
to the results in Finnish patients, and that is because the
mitotic and apoptotic activities are almost equal in BC,
and this is in consistent with other findings [24,28].
Conclusions
The results indicate that the differences in AI among the
three countries studied may be due to the known vari-
ation in the distribution of genetic markers in these
populations. Improvement in health care and introduc-
tion of screening programs, however, could be very help-
ful in the Libyan population and specific cutoff points
(of 4 and 18 apoptosis/mm2) of AI might be used as a
quantitative criterion for Libyan BC to separate the
patients into good, moderate and bad prognosis groups.
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